Pre-made Onartuzumab benchmark antibody ( Fab + di-Fc, anti-MET therapeutic antibody, Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-401
                                      Pre-Made Onartuzumab biosimilar, Fab + di-Fc, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture,  assay development,  animal model development,  PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) | 
|---|---|---|---|---|
| GMP-Bios-ab-401-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-401-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-401-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-401-xmg | >100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Onartuzumab biosimilar, Fab + di-Fc, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody | 
| INN Name | Onartuzumab | 
| Target | MET | 
| Format | Fab + di-Fc | 
| Derivation | Humanized | 
| Species Reactivity | Human | 
| CH1 Isotype | IgG1 | 
| VD LC | Kappa | 
| Highest_Clin_Trial (Jan '20) | Phase-III | 
| Est. Status | Discontinued | 
| 100% SI Structure | 4k3j:HL | 
| 99% SI Structure | None | 
| 95-98% SI Structure | None | 
| Year Proposed | 2010 | 
| Year Recommended | 2011 | 
| Companies | Chugai Pharmaceutical;Genentech | 
| Conditions Approved | na | 
| Conditions Active | na | 
| Conditions Discontinued | Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours | 
| Development Tech | na | 
 
        <
 
                
                 
             
         
         


